Seeking Alpha

Sarepta (SRPT +2.4%) CEO Chris Garabedian told the JPM healthcare conference yesterday...

Sarepta (SRPT +2.4%) CEO Chris Garabedian told the JPM healthcare conference yesterday (transcript) that his company's cash balance at the end of Q4 was $187M. Sarepta plans to meet the FDA in Q1 over its Eteplirsen drug for muscular dystrophy for end of Phase II discussions. If the talks are "favorable," Sarepta will look to file for an accelerated approval for the drug, which Garabedian reckons has a market of $600M-$1B in the U.S.
Comments (1)
  • cheap stock.

     

    enormous potenyial!
    10 Jan 2013, 04:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)